The deal allows Amicus to establish a presence in the UK, supporting the company’s other European offices in Munich, Paris, Madrid and Amsterdam. Phoenix House is situated in an excellent strategic location in Gerrard’s Cross, Buckinghamshire, and allows easy access to Junction 1 of the M40, providing a link to Central London and the M25.
Commenting on the deal, Cliff Jackson, director of office agency at Lambert Smith Hampton’s Maidenhead office, said: “The personal story behind Amicus and its aims and ambitions for the future gave extra impetus to us finding the ideal solution - a great operational platform for today with the flexibility for the future that a company with such exciting plans needs. With assistance from our building consultancy team who managed the fit-out, Phoenix House has provided this and we look forward to assisting this worthy organisation with its success in the future.”
Amicus, which is headquartered in Cranbury, New Jersey, develops advanced therapies to treat a range of devastating rare diseases and currently has a robust development pipeline of novel, first-in-class treatments for a broad range of human genetic diseases. The company is currently seeking global approvals of its lead product candidate, a personalised medicine in late-stage development to treat individuals with Fabry disease.
Amicus is managed by John F. Crowley, who’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease, a severe and often fatal neuromuscular disorder. John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand - The Cure: How a father raised $100 million and bucked the medical establishment in a quest to save his children. The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is also inspired by the Crowley family journey.